MYOVのニュース
Sumitovant Buys Myovant 2023/03/10 16:47:03 The Middle Market
Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal valued at $1.7 billion.
1.39B Reasons To Be Bullish On Myovant Sciences Stock 2023/03/10 15:03:10 Benzinga
Sumitomo Chemical Co Ltd , 10% Owner at Myovant Sciences (NYSE: MYOV ), reported a large insider buy on March 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Ltd purchased 51,599,200 shares of Myovant Sciences. The total transaction amounted to $1,393,178,400. Myovant Sciences shares are trading up 0.06% at $27.0 at the time of this writing on Friday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily … Full story available on Benzinga.com
Myovant Sciences earnings missed by $0.14, revenue fell short of estimates By Investing.com 2023/01/27 02:08:00 Investing.com
Myovant Sciences earnings missed by $0.14, revenue fell short of estimates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M 2023/01/26 21:27:46 Seeking Alpha
Myovant Sciences press release (MYOV): Q3 GAAP EPS of -$0.56 beats by $0.08.Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M.Cash, cash equivalents, marketable securities, and…
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 2023/01/26 21:05:00 GlobeNewswire
BASEL, Switzerland, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy, today announced financial results for the third quarter of fiscal year 2022 and provided other corporate updates.
Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer 2022/04/04 15:08:00 Kwhen Finance
Myovant Sciences Ltd. (NYSE: MYOV) Has Succeeded In Generating Interest In 2022, The Stock Is Down -12.33% Year-To-Date 2022/03/26 13:00:00 Marketing Sentinel
Myovant Sciences Ltd. (NYSE:MYOV)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 2.74. At the close of trading, the stock’s price was $13.65, to imply a decrease of -5.01% or -$0.72 in intraday trading. The MYOV share’s 52-week high remains $27.43, putting it -100.95% down since that … Myovant Sciences Ltd. (NYSE: MYOV) Has Succeeded In Generating Interest In 2022, The Stock Is Down -12.33% Year-To-Date Read More »
Myovant secures European recommendation for prostate cancer therapy 2022/02/25 15:05:50 Seeking Alpha
Commercial-stage pharma company, Myovant Sciences <> announced Friday that an expert panel of the European Medicines Agency ((EMA)) issued a positive opinion on Orgovyx for…
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript 2022/01/26 20:18:06 Seeking Alpha
Myovant Sciences GAAP EPS of -$0.68 misses by $0.07, revenue of $54.4M in-line (NYSE:MYOV) 2022/01/26 11:56:04 Seeking Alpha
Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.68 misses by $0.07.Revenue of $54.4M (+3842.0% Y/Y) in-line.
Myovant secures European recommendation for prostate cancer therapy 2022/02/25 15:05:50 Seeking Alpha
Commercial-stage pharma company, Myovant Sciences <> announced Friday that an expert panel of the European Medicines Agency ((EMA)) issued a positive opinion on Orgovyx for…
Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q3 2021 Results - Earnings Call Transcript 2022/01/26 20:18:06 Seeking Alpha
Myovant Sciences GAAP EPS of -$0.68 misses by $0.07, revenue of $54.4M in-line (NYSE:MYOV) 2022/01/26 11:56:04 Seeking Alpha
Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.68 misses by $0.07.Revenue of $54.4M (+3842.0% Y/Y) in-line.